DOLGININA SVETLANA IGOREVNA,Долгинина Светлана Игоревна,KHOKHLUNOV SERGEJ MIKHAJLOVICH,Хохлунов Сергей Михайлович,RUBANENKO ANATOLIJ OLEGOVICH,Рубаненко Анатолий Олегович
申请号：
RU2014115133
公开号：
RU2555134C1
申请日:
2014.04.15
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
FIELD: medicine.SUBSTANCE: assessing a risk of recurrent atrial fibrillation (AF) is ensured by determining the patients age in years (A), the time following radio frequency ablation in months (B), postoperative inpatient recurrent atrial fibrillation (C), the degree of the aortic valve insufficiency (D), the left atrial diameter in mm (E), anti-arrhythmic therapy conducted (F) with F=l if the anti-arrhythmic therapy involves amiodarone, and F=2 if the anti-arrhythmic therapy with sotalol is conducted, the degree of the mitral valve insufficiency (J), the number of reference ablation points (I) the number of radio frequency applications (G) the radio frequency ablation type (H) with H=2 accompanying RF labyrinth, and H=3 with the radio frequency ablation of pulmonary vein basins and ganglia plexuses. The derived values are used to calculate the risk (R) of atrial fibrillation by three formulas. The highest of the three derived R values is further determined. If the highest R value has been derived by the first formula, the recurrent atrial fibrillation following the radio frequency ablation may not be predicted. The highest R value produced by the second formula enables predicting the recurrent atrial fibrillation to come during 6 months following the radio frequency ablation.The highest R value taken from the third formula shows that the recurrent atrial fibrillation is predicted to come during more than 6 months following the radio frequency ablation.EFFECT: method enables predicting the risk of the recurrent atrial fibrillation following the radio frequency ablation in the patients, pre-selecting a set of medical products necessary for the anti-arrhythmic and anti-coagulant treatment of the patient, pre-specifying a follow-up visit schedule and additional functional diagnostic techniques and considering if the repeated radio frequency ablation is required.2 exИзобретение относится к медицине, а именно к области кардиологии. Для оценки риска развития рецидива фибр
